Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Atrial Fibrillation – Unmet Need – Unmet Need – Atrial Fibrillation (US/EU)

Login to access report north_east
Contact sales account_box

Atrial fibrillation (AF) is characterized by irregular and frequently accelerated heartbeats in the atria. It is associated with severe cardiovascular diseases, notably an elevated risk of stroke, leading to substantial morbidity and mortality. To control heart rate and restore normal cardiac rhythm in AF patients, rate-control drugs such as metoprolol and diltiazem or rhythm control drugs such as flecainide are used. The directly acting oral anticoagulants (DOACs) like Eliquis and Xarelto aid in stroke prevention and have become widely used. In this report, we ask cardiologists to evaluate and compare current treatments and the attributes they consider important for treatment decisions. We also discuss the areas of unmet need and attributes that new drugs should exhibit to serve the AF patients and gain a competitive edge in the atrial fibrillation market.

QUESTIONS ANSWERED

  • How do cardiologists rate current AF drugs, such as Johnson & Johnson’s Xarelto and Bristol Myers Squibb’s Eliquis?
  • Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different efficacy and safety attributes would cardiologists be willing to make for a new drug for atrial fibrillation?
  • How can dosing frequency, route of administration, safety, and tolerability influence physician preference?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

  • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
  • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
  • Analyze market scenarios for different target product profiles using the TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European cardiologists fielded in February 2025

Key companies: Pfizer, Bristol Myers Squibb, Johnson & Johnson, Bayer, Amneal Pharmaceuticals, Wyeth Pharmaceuticals, Sun Pharmaceuticals, Bausch Health

Key drugs: Eliquis, Xarelto, metoprolol, flecainide, amiodarone, diltiazem hydrochloride, warfarin

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Heart Failure – Landscape & Forecast – Disease Landscape & Forecast (G7)
Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east